Koolen-de Vries Syndrome

Expressive speech and language abilities are central to functional outcomes in Koolen-de Vries Syndrome (KdVS), with impairments reflecting broader neurodevelopmental delay. Redenlab’s tools enable precise monitoring of communication progress, offering sensitive, scalable endpoints for use in natural history studies and interventional trials.

Koolen-de Vries Syndrome impacts communication at every stage

Koolen-de Vries Syndrome (KdVS) is a rare genetic neurodevelopmental condition characterised by intellectual disability, expressive language delays, and hypotonia, with many individuals remaining minimally verbal well into childhood. These challenges can limit independence, hinder social development, and place substantial emotional and logistical strain on families. Traditional assessments often lack the sensitivity to track subtle gains or regressions in expressive communication. Redenlab provides developmentally informed, low-burden speech and language assessments designed for minimally verbal populations, enabling objective measurement of progress in clinical and therapeutic studies.

Purpose-built communication assessment for KdVS trials

Designed for minimally verbal children

Tailored assessments capture pre-linguistic vocalisation, sound repertoire, and emerging speech patterns in low-verbal and verbal populations.

Sensitive to developmental change

Tracks both acquisition and loss of communication abilities over time, even in slow-progressing or plateaued profiles.

Supports natural history and early-phase trials

Validated protocols suited to rare, genetically defined cohorts with broad phenotypic variability.

Family-centred, remote-capable tools

Naturalistic, caregiver-supported assessments facilitate high-frequency data capture in home settings.

Objective metrics for expressive language

Quantitative analysis of vocal effort, articulation, and phonetic content provide consistent endpoints across sites and timepoints.

Redenlab’s KdVS experience

No. of studies: 3
No. of Patients assessed: 1,000
Redenlab partner with global clinical research leaders in KdVS. Our work with the Murdoch Children’s Research Institute in Melbourne and Radboud University Medical Center in Nijmegen, Netherlands has led to the comprehensive characterisation of speech and language features in the condition.